UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K
 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 7, 2010
 

RENHUANG PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in its Charter)
 
 
Nevada
  
0-24512
  
88-1273503
(State or Other Jurisdiction
of Incorporation)
  
(Commission File Number)
  
(IRS Employer
Identification No.)

No. 281, Taiping Road, Taiping District
Harbin, Heilongjiang Province, 150050
(Address of Principal Executive Offices)

Registrant’s telephone number, including area code:  86-451-5762-0378

N/A
(Former Name or Former Address, if Changed Since Last Report)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 

ITEM 2.02. Results of Operations and Financial Condition

On June 7, 2010, Renhuang Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the second quarter ended April 30, 2010. A copy of this press release is attached hereto as Exhibit 99.1.

The Company’s management team held a conference call on June 8, 2010 at 9:00 a.m. Eastern Time to review the aforementioned financial results. A replay of the conference call will be available from Tuesday June 8, 2010 at 10:00 a.m. Eastern Time through Tuesday June 22, 2010.  To access the replay, dial 800-642-1687. International callers should dial +1 706-645-9291.  The conference ID number for the call is 79282265.  A copy of the conference call transcript is attached hereto as Exhibit 99.2.

The information in this Item 2.02 of Form 8-K, including the accompanying exhibits, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that certain statements set forth in this Current Report on Form 8-K provide other than historical information and are forward looking. The actual achievement of any forecasted results, or the unfolding of future economic or business developments in a way anticipated or projected by the Company, involve numerous risks and uncertainties that may cause the Company’s actual performance to be materially different from that stated or implied in the forward-looking statement.

Item 7.01 Regulation FD Disclosure.

The response to Item 2.02 is incorporated herein by reference to this Item 7.01.

The information in Item 7.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that certain statements set forth in this Current Report on Form 8-K provide other than historical information and are forward looking. The actual achievement of any forecasted results, or the unfolding of future economic or business developments in a way anticipated or projected by the Company, involve numerous risks and uncertainties that may cause the Company’s actual performance to be materially different from that stated or implied in the forward-looking statement.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.
  
Description
99.1*
  
Press Release dated June 7, 2010 announcing second quarter 2010 financial results
99.2*
  
Conference Call Transcript dated June 8, 2010

*
  
Such Exhibit is being “furnished” (not filed) pursuant to Item 2.02 and Item 7.01 of the Current Report on Form 8-K.
 
 
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
   
RENHUANG PHARMACEUTICALS, INC.
     
Date: June 9, 2010
  
By:
  
/s/ Shaoming Li
       
Shaoming Li
       
Chief Executive Officer
 
 
 
 
 
EXHIBIT INDEX
 
Exhibit
    
Number
  
Description
99.1*
  
Press Release dated June 7, 2010 announcing first quarter 2010 financial results
99.2*
  
Conference Call Transcript dated June 8, 2010

*
  
Such Exhibit is being “furnished” (not filed) pursuant to Item 2.02 and Item 7.01 of the Current Report on Form 8-K.